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with treatment (P  0.001). Although subjective compli-
ance declined as PEI score declined, the relationship was
not statistically significant. A significant relationship was
found between treatment and PEI score (P  0.05), with
more patients in the candesartan cilexetil group achieving
control with low side-effects and fewer falling into the
high impact category. CONCLUSION: Results suggest
the PEI is a useful summary indicator of the efficacy of a
given agent relative to the patient’s perception of tolera-
bility. Further study of the predictive value of this index
in terms of drug-switching and long-term compliance in
hypertension and the usefulness of this type of system for
other products and indications is warranted.
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BACKGROUND: Rates of patient adherence (compli-
ance) range from as low as 8% to over 100%. Among
factors negatively influencing adherence are multiple daily
dosing (MDD), chronic duration, and asymptomatic dis-
ease. Inconsistent reports suggest single daily dosing
(SDD) may be associated with improved adherence. OB-
JECTIVES: This meta-analysis compared SDD to MDD
and twice daily regimens (BID) with regard to adherence
rates for antihypertensive pharmacotherapy. METH-
ODS: Medline, IPA and Embase searches located com-
parative trials in adults taking oral solid dosage forms. A
random effects model was used to combine and analyze
data. RESULTS: We included eight primary studies in the
analysis, examining 11,485 patients (1830 for SDD,
4405 for BID, 4147 for [BID], and 9655 for all MDD).
The mean rate for SDD  SE (91.4%  2.2%) was sig-
nificantly higher (Z  4.46, P  0.001) than MDD
(83.2%  3.5%). The mean rate for SDD (92.7% 
2.3%) was also significantly higher (Z  2.22, P 
0.026) than BID (87.1%  2.9%). The difference be-
tween BID (90.8%  4.7%) and [BID] (86.3% 
6.7%) was not statistically significant (Z  1.82, P 
0.069). DISCUSSION: This literature-based meta-analy-
sis update confirms our previous findings showing SDD
to be associated with better adherence than both BID and
MDD in hypertension. Consequently, SDD may further
induce a decrease in morbidity, relapse rates, and hospi-
tal admissions. However, those who do not fully adhere
to SDD may present an increased risk of relapse by miss-
ing their daily dose. CONCLUSION: Our meta-analysis
supports the association of once-daily regimens with bet-
ter adherence to antihypertensive pharmacotherapy. Fur-
ther research is warranted to validate findings for other
diseases.
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OBJECTIVE: To assess the effect of polypharmacy on
hospitalization rates in an elderly CHF Medicaid popula-
tion. METHODS: All subjects possessing diagnoses
codes indicative of CHF (ICD9-CM  402.01, 402.11,
428, 402.91, 404.01, 404.02) greater than 59 years of
age at first diagnosis in the South Carolina Medicaid pro-
gram between 1993–1995 were eligible for inclusion.
Subjects were excluded if they resided in a nursing facility
which precluded access to their drug utilization. Poly-
pharmacy was defined as actively taking more than 3.5
prescriptions per day in the first year following the initial
CHF diagnosis. Hospitalization was modeled using logis-
tic regression and time to hospitalization was analyzed
using survival analysis. Propensity score methods were
used to adjust for treatment bias. A subject’s prior year
costs and number of comorbidities were used as surro-
gate controls for severity. RESULTS: A total of 702 sub-
jects met all inclusion criteria. The mean age was 67.35
(SD  8.9) and 79.5% were female. Nearly 58% of sub-
jects were hospitalized in the 2 years following the initial
diagnosis. Polypharmacy was not significantly associated
with hospitalization (OR  1.22, 95%CI 0.72–1.71) or
time to hospitalization (RR  1.042, 95%CI 0.08–1.34).
Increasing number of comorbidities was significantly as-
sociated with hospitalization (OR  1.75, 95%CI 1.26–
2.44) and time to hospitalization (RR  1.16, 95%CI
1.07–1.27). CONCLUSIONS: Polypharmacy does not
appear to affect hospitalization rates in the first year fol-
lowing initial diagnosis. Analysis of the log survival func-
tion plot, however, suggests polypharmacy may increase
the likelihood of hospitalization in the second year.
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Secondary prevention plays a significant role in decreas-
ing recurrent myocardial infarction and cardiovascular
mortality. In reducing patient risk, medication effective-
ness is dependent on patient compliance. OBJECTIVE:
We conducted a retrospective pilot study to assess patient
compliance with aspirin, beta-blocker, ACE inhibitor, and
lipid-lowering therapy approximately two years after an
acute myocardial infarction. METHODS: At the Univer-
sity of Michigan Medical Center, 199 consecutive patients
admitted to the Cardiology service in 1997 and discharged
alive with acute myocardial infarction were prospectively
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identified and charts were abstracted retrospectively. At
follow-up, 122 patients completed a telephone survey ad-
dressing 11 quality of care indicators and current medica-
tions. Four medication classes were compared at dis-
charge and at follow-up. RESULTS: On average, patients
were 60.9 years and male (75.4%) with Q-type of infarc-
tion upon presentation (50%). Patients lost to follow-up
did not differ demographically (P  0.05). At follow-up,
aspirin compliance was 96.6%; beta-blocker was 79.3%;
ACE inhibitor was 50.7%; lipid-lowering agent was
86.4% [higher than 4S study (P  0.005)]. Follow-up
metoprolol compliance was 63.4%. For ACE inhibitors,
only 25.5% remained on the same medication and
27.5% had switched brands. A 20% increase in com-
pliance from discharge to follow-up with lipid-lowering
agents was seen. Congestive heart failure was associated
with non-compliance with beta-blocker and compliance
with ACE inhibitor therapy. No age trends in medication
compliance were seen. CONCLUSION: Aspirin therapy
had the highest compliance rate at follow-up, followed
by lipid-lowering agents, beta-blockers and ACE inhibi-
tors. Since patients on lipid-lowering agents tended to
have higher ACE inhibitor compliance, physician moni-
toring of lipids may indirectly increase medication com-
pliance and secondary prevention.
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OBJECTIVE: Although assessment of health-related qual-
ity of life (HRQOL) as an outcome in multi-center clini-
cal trials is common, little is known about inherent inter-
national patient differences. Thus, we sought to evaluate
the effects of nationality in an international post-MI pop-
ulation. METHODS: In the GUSTO-I Angiographic
Trial, 1848 patients (pts) from 10 countries were con-
tacted for HRQL telephone interviews 2 yrs post infarct
(87.7% response). Questionnaires translated (forward/
backward) into French, Dutch, German, and Spanish
measured physical function (Duke Activity Scale), emo-
tional function (Minn Living with Heart Failure), social
function and perceived health (MOS SF-36), and symp-
toms (angina and dyspnea). Nationality was coded as US,
Canada (CN), Australia (AU), and Europe (EU). Struc-
tural equation modeling (SEM) was used to evaluate na-
tionality’s effect on HRQL, symptoms, and disease sever-
ity. RESULTS: At baseline, US pts had significantly more
comorbidity than CN pts and more revascularization
procedures than the other patients groups. In univariate
analyses, no differences among nationalities were present
in any HRQL outcomes. In the SEM (which controlled
for disease severity and symptoms) nationality did not
have a significant impact on HRQL, despite EU pts re-
porting more angina and dyspnea than US pts (P  0.0001)
and more dyspnea than CN pts (P  0.001). CONCLU-
SION: In this sample of homogenous post MI pts from
similar Westernized cultures, nationality did not impact
HRQL. Although differences may exist in more heteroge-
nous samples, these findings suggest that pooling similar
Westernized culture’s outcome data is valid.
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While costs and outcomes for cerebrovascular events
have been estimated for large, university-based medical
centers, similar studies in community hospitals are lack-
ing. OBJECTIVE: To compare costs of care, length of
stay and mortality for patients with subarachnoid hemor-
rhage (SAH), intracerebral hemorrhage (ICH), ischemic
cerebral infarction (ICI) and transient ischemic attacks
(TIA) for patients treated in community teaching (CT)
and nonteaching (CNT) hospitals in the US. METHODS:
A retrospective cohort design was used, employing data
from HBSI’s national data warehouse from community
hospitals. Comparative costs are calculated using a stan-
dardized general ledger approach to derive direct and in-
direct costs. Wilcoxon signed rank tests were used to test
for differences in costs and length of stay. Chi-square
tests were used to test for differences in mortality. RE-
SULTS: The sample consisted of 1,244 patients treated in
1998 with SAH, 3,633 with ICH, 16,066 with ICI, and
9,276 with TIA from 137 hospitals. Mean costs for inpa-
tient care were $4,058 higher in CT hospitals for SAH,
$3,135 for ICH, $434 for ICI and $216 for TIA (P 
0.001 for each). Length of stay was 0.48 days longer for
SAH patients and 1.5 days longer for ICH patients
treated at CT hospitals (P  0.005). There were no sig-
nificant differences between CT and CNT hospitals for
inpatient mortality, severity of illness or risk of mortality
for these events. CONCLUSION: Based on unadjusted
estimates of costs and mortality rates, patients with CV
events treated at CT hospitals may incur higher costs
without any apparent benefit in mortality.
